tbuckley/cabot-search huggingface dataset:
Prostate-specific antigen (PSA) regulates expression of osteoblast-associated genes and induces osteoblastic differentiation of human osteosarcoma cell line SaOS-2
Authors: Farideh Mehraein-Ghomi, Soo Lee, Wei Lou, Akeila Bellahcene, Keith L. Kirkwood, Allen C. Gao
Journal: Cancer Research (2004)

4481   Translational research in prostate cancer is limited by the availability of tumor specimens. A rapid autopsy (RA) program, supported by SPORE P50 CA69568 and CaPCURE, is ongoing at the University of Michigan (U of M) to obtain tumor tissues. We previously reported a series of rapid autopsies of 14 patients with hormone refractory prostate cancer (HRPC) 1 . Here we update this series for a total of 30 cases. Patients with HRPC at the U of M are informed of the RA program and are consented for autopsy. Within hours of their death, specimens are collected as fresh tissue, snap frozen tissue in liquid nitrogen, or formalin fixed tissue. From September 1996 to September 2003, 30 patients have participated in the RA program. The initial Gleason Score was not known for 6 patients. 9 patients (30.0%) had a Gleason Score of 9, 11 (36.7%) had a score of 7 or 8, and 4 (13.3%) had a score of 6 or less. Primary therapy consisted of prostatectomy for 6 patients (20%) and radiotherapy for 13 (43.3%). Salvage or palliative radiotherapy was given to 13 patients (43.3%). 23 patients (76.7%) received combined androgen blockade, and 11 (36.7%) underwent orchiectomy. 28 patients received chemotherapy (93.3%). 20 of 22 patients (90.9%) with intact prostates had prostatic involvement. Lymph nodes were involved in 23 patients (76.7%) with thoracic nodes seen in 14 and retroperitoneal lymph nodes noted in 15 patients. Mesenteric lymph nodes were seen in 3 patients. Bone lesions included vertebral lesions in 21 patients (70%), rib lesions in 12 (40%), skull metastases in 5 (16.7%), pelvic bone lesions in 2 (6.7%), and other bone metastases in 6 patients. Visceral metastases included liver lesions in 19 patients (63.3%), lung metastases in 14 (46.7%), dural metastases in 11 (36.7%), adrenal lesions in 7 (23.3%), and histologic evidence of brain metastases in 4 patients (13.3%). Metastases to mediastinum, pleura, stomach, pancreas, small intestine, peritoneum, bladder, and pelvic cavity each occurred in 2 to 5 patients. Metastases to the kidney, diaphragm, right ventricle, thyroid, colon, spleen, and spermatic cord were each seen in single patients. 8 patients (26.7%) had incidental neoplasms present. Procured tissue has been used to create xenografts 1 , and work is ongoing to establish cell lines and to isolate RNA for microarray analysis.  1 Rubin,  Clin. Can. Res ., 6: 1038-1045, 2000.
Studies on the Structure of the Pulmonary Trunk
Authors: MARIO SALDAÑA, JAVIER ARIAS-STELLA
Journal: Circulation (1963)

Measurements of the thickness of the media of the pulmonary trunk and ascending aorta were made in 200 normal autopsy cases ranging in ages from birth to 80 years. One hundred cases were persons who were born and lived permanently in places between 11,300 to 14,900 feet above sea level. One hundred persons of comparable ages, born at sea level, served as control. It is shown that at high altitudes the pulmonary trunk exhibits a thicker media than at sea level, in the course of the whole of life. This fact is explained by the occurrence, at high altitudes, of a mild degree of pulmonary arterial hypertension from birth. The media of the ascending aorta of high altitude natives was found to be thinner than that of sea level inhabitants, after 30 years. This characteristic appears to be related to the existence of a lower systolic pressure at high altitudes than at sea level.
BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial
Authors: B. Massuti Sureda, J.M. Sanchez Torres, M. Cobo Dols, M.T. Moran Bueno, J.L. Gonzalez-Larriba, I.C. Barneto Aranda, J. De Castro Carpeno, L. Iglesias, M.A. Muñoz, G. López Vivanco, M.D. Isla Casado, R. López, R. de las Penas Bataller, D. Rodriguez Abreu, A. Artal-Cortes, E. Esteban, M. Provencio, E. Pereira, J. Sanchez-Paya, R. Rosell
Journal: Annals of Oncology (2019)
JIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status
Authors: M. Tsuboi, H. Kenmotsu, T. Yamanaka, K. Yoshiya, T. Takahashi, T. Ueno, K. Goto, H. Daga, N. Ikeda, K. Sugio, T. Seto, S. Toyooka, H. Date, T. Mitsudomi, I. Okamoto, K. Yokoi, H. Saka, H. Okamoto, Y. Takiguchi, N. Yamamoto
Journal: Annals of Oncology (2019)
Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours
Authors: R.B. Corcoran, K.T. Do, J.M. Cleary, A.R. Parikh, O.O. Yeku, C.D. Weekes, J. Veneris, L.G. Ahronian, G. Mauri, E.E. Van Seventer, I.J. Fetter, J.M. Gurski, U.A. Matulonis, D. Juric, K.T. Flaherty, R.J. Sullivan, J.W. Clark, R.S. Heist, G.I. Shapiro
Journal: Annals of Oncology (2019)
Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study
Authors: D.H. Enrico, L. Lacroix, E. Rouleau, J.-Y. Scoazec, Y. Loriot, L. Tselikas, C. Jovelet, D. Planchard, A. Gazzah, L. Mezquita, M. Ngo, S. Michiels, C. Massard, F. Facchinetti, J. Chen, J.-C. Soria, F. André, G. Vassal, L. Friboulet, B. Besse
Journal: Annals of Oncology (2019)
a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)
Authors: Jason B Kaplan, Dale L. Bixby, John C Morris, Olga Frankfurt, Jessica Altman, Trisha Wise-Draper, Patrick W. Burke, Sabrina Collins, Karuppiah Kannan, Ling Wang, Stephanie Faucette, Benjamin Lee, Yaping Shou, Mark J. Levis, Keith W. Pratz
Journal: Blood (2016)
Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Authors: U. Wiedermann, E. Garner-Spitzer, Y. Chao, I. Bulat, A. Dechaphunkul, W. Arpornwirat, C. Charoentum, C.J. Yen, T. Yau, M. Maglakelidzde, S. Tanasanvimon, J. Maneechavakajorn, A. Sookprasert, L.-Y. Bai, W.-C. Chou, T. Ungtrakul, C.C. Zielinski, L. Chong, N. Ede, A. Good
Journal: Annals of Oncology (2019)
Feasibility of a self-screening for insomnia and acceptability of an online targeted video-based cognitive behavioral program in cancer outpatients: SLEEP-4-ALL-1 study design
Authors: C. Charles, D. Boinon, L. Fasse, J. Journiac, G. Pallubicki, G. Ninot, E. Ninot, S. Gouy, J. Savard, S. Dauchy
Journal: Annals of Oncology (2019)

Background: Insomnia is a distressing and an enduring problem that affects between 25 and 59% of cancer patients during and after treatments. Despite its association with reduced quality of life, negative psychological symptoms and cancer-related fatigue, this major concern remains insufficiently assessed and managed in routine care. Cognitive-Behavioural Therapy for Insomnia (CBT-I) is considered as the non-pharmalogical gold standard treatment. However, one main limitation is the practical implementation of the intervention because of the lack of trained professionals in cancer care settings and geographic distances from therapeutics resources. The frequent presence of somatic comorbidities, such as fatigue or pain, can also complicate access to care. New technologies open innovative ways to facilitate access to targeted interventions, such as online attractive and easy-to-use programs. Trial design: Designed as close as possible to the usual care conditions, the monocentric pilot study SLEEP-4-ALL-1 mains, first, to determine the feasibility of a systematic self-screening for insomnia in a population of 400 French adult cancer outpatients with breast, colorectal, pulmonary or urological cancer, using the Insomnia Severity Index (ISI); second, to evaluate among patients with insomnia the acceptability of an online video-based CBT-I, validated in a Quebec breast cancer survivors sample by Savard's team, with a mixed method approach (quantitative and qualitative). Inclusions are currently completed. SLEEP-4-ALL-1 study, funded by the French National Institute of Cancer (INCA), corresponds to the development phase of a multicentric randomized controlled trial (SLEEP-4-ALL-2) which aims to test an online stepped-care model in the treatment of persistent insomnia, that can provide patients and health professionals an efficient, easily available, replicable, and cost-effective therapeutic solution. Legal entity responsible for the study: Gustave Roussy Cancer Center. Funding: French National Institute of Cancer (INCA): Interventional Research in Public Health Call. Disclosure: All authors have declared no conflicts of interest.
The role of the study nurse in clinical research
Authors: C. Tonnini, R. Berardi, S. Ciattaglia, F. Coppari, A. Del Nero, V. Di Censo, L. Francioso, M. Francoletti, L. Fuligni, M. Olivieri, F. Vitarelli, I. Zoppi
Journal: Annals of Oncology (2016)
Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: A single Spanish hospital experience
Authors: M D Mediano Rambla, J.A. Marcos, R. Carrillo, M. Espinosa, F. Sanchez, M.D. Alvardado, L. Rendon, J J Reina Zoilo, A. Albero
Journal: Annals of Oncology (2019)
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
Authors: Rina Hui, Mustafa Özgüroğlu, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Jhanelle E Gray, Anna Rydén, Louis Viviers, Lynne Poole, Yiduo Zhang, Phillip A Dennis, Scott J Antonia
Journal: The Lancet Oncology (2019)
RIbociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer: RIGHT choice study
Authors: N. El Saghir, S. Malwinder, H. Azim, Y. Eralp, S.-A. Im, Y.S. Yap, T. Delgar Alfaro, M. Gao, Y.-S. Lu
Journal: Annals of Oncology (2019)
Enteric bacteria induce IFNγ and Granzyme B from human colonic Group 1 Innate Lymphoid Cells
Authors: Moriah J. Castleman, Stephanie M. Dillon, Christine Purba, Andrew C. Cogswell, Martin McCarter, Edward Barker, Cara Wilson
Journal: Gut Microbes (2019)

Group 1 Innate Lymphoid Cells (which include Natural Killer cells and ILC1s) aid in gut anti-bacterial defense through the production of IFNγ, which is critical for mobilizing protective responses against enteric pathogens. When intestinal epithelial barrier integrity is compromised, commensal bacteria are likely to translocate from the gut lumen into the lamina propria. Few studies have addressed the mechanisms by which commensal bacteria impact the function of gut Group 1 ILCs, especially ILC1s. Utilizing an in vitro human colonic lamina propria mononuclear cell (LPMC) model, we evaluated Group 1 ILC cytokine and cytolytic protein production in response to a panel of enteric Gram-positive and Gram-negative commensal and pathogenic bacteria. IFNγ-production by NK cells and ILC1s was significantly increased after LPMC exposure to Gram-negative commensal or pathogenic bacteria, but not after exposure to the Gram-positive bacteria commensals tested. Stimulation of IFNγ production from Group 1 ILCs was not through direct recognition of bacteria by NK cells or ILC1s, but rather required accessory cells within the LPMC population. Myeloid dendritic cells generated IL-12p70, IL-18, and IL-1β upon exposure to enteric bacteria and these cytokines contributed to Group 1 ILC production of IFNγ. Furthermore, Gram-negative commensal or pathogenic bacteria induced significant expression of Granzyme B in NK cells and ILC1s. Overall, these data demonstrate that some enteric commensal bacteria indirectly induce inflammatory cytokine production and cytolytic protein expression from human colonic Group 1 ILCs, a process which could contribute to inflammation in the setting of microbial translocation.
Fundamentals of Anesthesia: An Outline
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
Authors: Jorge E. Cortes, Franck Emmanuel Nicolini, Andreas Hochhaus, Philipp D. le Coutre, Dong-Wook Kim, Javier Pinilla-Ibarz, Ronald Paquette, Charles Chuah, Jane F. Apperley, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Martin C. Mueller, Carlo Gambacorti-Passerini, Fausto Castagnetti, Stephanie Lustgarten, Frank Neumann, Timothy P. Clackson, Francois Guilhot, Michael W. Deininger, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian
Journal: Blood (2017)
Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
Authors: A.X. Zhu, P.R. Galle, J.M. Llovet, R.S. Finn, Y.-K. Kang, C.J. Yen, E. Assenat, G. Brandi, K. Motomura, I. Ohno, B. Daniele, A. Vogel, T. Yamashita, C.-H. Hsu, T. Meyer, R. Widau, W. Schelman, C. Wang, Y. Hsu, M. Kudo
Journal: Annals of Oncology (2019)
Advanced ovarian cancer: Is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?
Authors: M. Bartoletti, S. Gagno, E. Poletto, M. Garziera, S. Scalone, E. Dreussi, C. Zanusso, R. Roncato, E. Cecchin, E. De Mattia, R. Sorio, G. Giorda, L. Quartuccio, S. De Vita, C. Romualdi, F. Puglisi, G. Toffoli
Journal: Annals of Oncology (2019)
XPO1 Inhibition By Selinexor Synergizes with BCR Inhibition, Blocks Tumor Growth and Prolongs Survival in a Bioluminescent Animal Model of Primary Central Nervous System Lymphoma
Authors: Marta Crespo, Julia Carabia, Isabel Jiménez, Sabela Bobillo, Pau Abrisqueta, Carles Palacio, Cecilia Carpio, Josep Castellvi, Noelia Purroy, Joan Seoane, Francesc Bosch
Journal: Blood (2016)
Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial
Authors: I.L.M. Reijers, E.A. Rozeman, A.M. Menzies, J.M. Versluis, B.A. van de Wiel, K. Sikorska, H. Eriksson, K. Shannon, C. Bierman, H. van Tinteren, M. Gonzalez, A.J. Spillane, R.P. Saw, R.A. Scolyer, A.C.J. van Akkooi, J. Hansson, G.V. Long, C.U. Blank
Journal: Annals of Oncology (2019)
Markers of systemic inflammation correlate with survival prognosis in patients with newly diagnosed brain metastases
Authors: A.M. Starzer, C. Deischinger, A. Steindl, M. Mair, G. Widhalm, J.M. Frischer, B. Gatterbauer, C. Marosi, K. Dieckmann, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2019)
A phase Ib trial of neoadjuvant chemoradiotherapy and durvalumab (MEDI4736) for potentially resectable stage III non-small cell lung cancer (NSCLC)
Authors: B.C. Ahn, S. Lee, J.W. Seo, C.Y. Lee, J.G. Lee, S.Y. Park, D.J. Kim, C.G. Lee, J. Cho, H.I. Yoon, B.Y. Shim, D.G. Cho, S.W. Kim, H.S. Park, Y.J. Chun, M.H. Hong, H.R. Kim, B.C. Cho
Journal: Annals of Oncology (2019)
Single center experience of perioperative EOX in locally advanced resectable gastroesophageal cancer (GEC).
Authors: Angela Djanani, Georg Pall, Oliver Edgar Bechter, Reinhold Kafka-Ritsch, Matthias Zitt, Johann Pratschke, Marie-Therese Kasseroler, Wolfgang Eisterer
Journal: Journal of Clinical Oncology (2012)

e14719 Background: Perioperative chemotherapy has shown to improve local control and survival in GEC (MAGIC, FFCD, EORTC40954) deploying 5-FU and cisplatin ± epirubicin. A triple chemotherapy with EOX (epirubicin, oxaliplatin, capecitabine) showed a promising response rate and an improved outcome in stage IV disease (REAL2). Methods: We analyzed 24 patients with locally advanced GEC (uT2N+, uT3N0-3, UICC II-IV) treated in our institution from 2008 to 2011 who received neoadjuvant EOX (epirubicin 50mg/qm iv d1 qd22, oxaliplatin 130mg/qm iv d1 qd22, capecitabine 1650mg/qm daily) followed by surgery followed by adjuvant EOX. The aim of this study was to retrospectively analyze the efficacy and toxicity of perioperative EOX and the treatment efficacy. Results: We treated 6 (25%) females and 18 (75%) male patients. Stage distribution was 42% UICC stage II, 50% stage III and 8% stage IV (cT1-4N3M0). All patients received neoadjuvant EOX. Dose reductions were necessary in 4/24 patients (17%). No treatment related deaths occurred. Main toxicities were grade 3/4 leucopenia 4/24 patients (17%), thrombopenia 2/24 patients (8%), diarrhea 3/24 patients (12%, CTC criteria 2.0). One patient suffered from a myocardial infarction after the third cycle of chemotherapy. Progression of disease was observed in 2 patients (8%). Surgery was performed in 21/24 patients (88%) with R0-resection rate of 100%. We recorded no major surgical complication. Downstaging assessed by histopathological response was achieved in 10 patients (48%) with complete pathological remission (CPR) in 2 patients (10%). 10 patients (42%) received adjuvant therapy. 54% of the patients are still alive and in complete remission. after a follow up period of 2 years. One patient died because of a cardiac arrest 2 weeks after surgery. Conclusions: Preoperative chemotherapy with EOX causes moderate toxicity and is associated with a meaningful clinical activity. The significant downstaging in locally advanced GEC suggests that this regiment is highly active in locally advanced gastric cancer. According to our experience EOX represents a valid alternative to cisplatin and 5FU ± epirubicin chemotherapy in curatively treated GEC.
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumours (mGISTs)
Authors: D. Fanale, L. Incorvaia, G. Badalamenti, J.L. Iovanna, D. Olive, I. De Luca, M. Silletta, B. Vincenzi, V. Bazan, A. Russo
Journal: Annals of Oncology (2019)
Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study
Authors: F. Lecuru, E. Pujade-Lauraine, S. Hamizi, A. Caumont-Prim, N. Raban, E. Malaurie, P. Pautier, M.-C. Kaminsky-Forrett, J. Meunier, J. Alexandre, D. Berton-Rigaud, N. Dohollou, C. Dubot, A. Floquet, L. Favier, L. Venat-Bouvet, M. Fabbro, C. Louvet, A. Lortholary, G. Ferron
Journal: Annals of Oncology (2019)
EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy
Authors: M. Kostine, A. Finckh, C.O. Bingham, K. Visser, J. Leipe, H. Schulze-Koops, E. Choy, K. Benesova, T. Radstake, A. Cope, O. Lambotte, J.-E. Gottenberg, Y. Allenbach, S. Jamal, A. Marabelle, J.M.G. Larkin, J B A G Haanen, L. Calabrese, X. Mariette, T. Schaeverbeke
Journal: Annals of Oncology (2019)
Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project
Authors: E. Aranda Aguilar, J. Garcia Foncillas, A. Antón, C.J. Camps Herrero, A. Carrato Mena, M. Constenla Figueiras, J.J. Cruz Hernandez, E. Diaz Rubio, P.N. Gascon, V. Guillem Porta, R. López, M. Feyjóo, J. Puente
Journal: Annals of Oncology (2019)
Prognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer
Authors: P. Foukas, G.-A. Koliou, A. Papoudou-Bai, A. Charchanti, E. Vrettou, C. Poulios, K. Chatzopoulos, V. Kotoula, E. Fountzilas, R. Zakopoulou, A. Visvikis, G. Pentheroudakis, D.G. Pectasides, G. Aravantinos, G. Oikonomopoulos, A. Papanikolaou, D. Haidopoulos, F. Zagouri, G. Fountzilas, A. Goussia
Journal: Annals of Oncology (2019)
Circadian rhythm–dependent and circadian rhythm–independent impacts of the molecular clock on type 3 innate lymphoid cells
Authors: Qianli Wang, Michelle L. Robinette, Cyrielle Billon, Patrick L. Collins, Jennifer K. Bando, José Luís Fachi, Cristiane Sécca, Sofia I. Porter, Ankita Saini, Susan Gilfillan, Laura A. Solt, Erik S. Musiek, Eugene M. Oltz, Thomas P. Burris, Marco Colonna
Journal: Science Immunology (2019)

Clock protein REV-ERBα influences development of type 3 innate lymphoid cells in a circadian-independent manner (see the related Focus by Mortha and Research Article by Teng et al. ).
Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumours with favorable outcome
Authors: M D M Noblejas López, C. Nieto-Jiménez, S. Morcillo-García, J. Pérez-Peña, M. Nuncia-Cantarero, E.M. Galán-Moya, E. Amir, A. Pandiella, B. Győrffy, A. Ocaña
Journal: Annals of Oncology (2019)
A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours
Authors: D.R. Camidge, F. Janku, A Martinez Bueno, D.V. Catenacci, J. Lee, S.-H. Lee, H.C. Chung, A. Dowlati, K.S. Rohrberg, E. Felip Font, E. Garralda, Y.-K. Kang, Y.W. Moon, M. López Criado, C.-F. Chiu, T.T. Poulsen, H. Rudbæk, L. Alifrangis, R.P. Dalal, A. Patnaik
Journal: Annals of Oncology (2019)
Dual Function of Magnesium in Bone Biomineralization
Authors: Jinglun Zhang, Lin Tang, Haoning Qi, Qin Zhao, Yan Liu, Yufeng Zhang
Journal: Advanced Healthcare Materials (2019)

Magnesium (Mg2+ ), as a main component of bone, is widely applied to promote bone growth and regeneration. However, Mg2+ can chemically inhibit the crystallization of amorphous calcium phosphate into hydroxyapatite (HA). The underlying mechanisms by which Mg2+ improves bone biomineralization remain elusive. Here, it is demonstrated that Mg2+ plays dual roles in bone biomineralization from a developmental perspective. During embryonic development, the Mg2+ concentration is enriched in the early stage from embryonic day 13.5 (E13.5) to E15.5, but gradually decreases to a stable state in the late phase, after E15.5. Appropriate concentrations of Mg2+ can promote the mineralization of bone marrow mesenchymal stem cells, while excessive Mg2+ impairs their osteogenesis. The earlier the Mg2+ is added, the stronger the observed inhibition of mineralization. In particular, less Mg2+ is present in fully mineralized collagen than in poorly mineralized collagen. Furthermore, a high concentration of Mg2+ changes the crystalline morphology of HA and inhibits collagen calcification. Functionally, a high-Mg2+ diet inhibits bone biomineralization in mouse offspring. Taken together, the results suggest that appropriate regulation of Mg2+ concentration over time is vital for normal biomineralization. This study is significant for the future design of bone substitutes and implants associated with Mg2+ content.